Author(s):
Shivangi Das, Geetanjali Sahu, Suruchi Prasad
Email(s):
shividas24@gmail.com , geetanjali.sahu574@gmail.com , psuruchi06@gmail.com
DOI:
10.52711/2231-5713.2025.00027 
Address:
Shivangi Das1, Geetanjali Sahu2, Suruchi Prasad3
1Behind Police Line Gharghoda Ward No 13, Rigarh, Chhattisgarh.
2C14 in front of Shree Krishna Vihar near Ashok Vihar Phase 2, Chantideeh, Bilaspur, Chhattisgarh.
3House No. 193, Nand Kishor Vihar Colony 27 Kholi Chowk, Bilaspue, Chhattisgarh.
*Corresponding Author
Published In:
Volume - 15,
Issue - 2,
Year - 2025
ABSTRACT:
Wet age-related macular degeneration (wet AMD) is a prevalent retinal disease characterized by abnormal growth of blood vessels beneath the macula, leading to vision loss. Current treatment modalities such as intravitreal injections pose challenges related to frequent administration and potential complications. In-situ gel formulations offer a promising alternative for sustained drug delivery directly to the affected site. This review discusses the formulation strategies and evaluation parameters for in-situ gels designed for the treatment of wet AMD, highlighting their potential advantages and challenges. Key factors influencing the gel properties, including gelation mechanism, biocompatibility, and drug release kinetics, are elucidated. Furthermore, recent advancements in polymer science and nanotechnology have enabled the development of innovative formulations with enhanced therapeutic efficacy and patient compliance. Future directions in research and clinical applications of in-situ gels for wet AMD management are also addressed, emphasizing the need for comprehensive preclinical and clinical studies to validate their safety and efficacy.
Cite this article:
Shivangi Das, Geetanjali Sahu, Suruchi Prasad. A Review on Formulation and Evaluation of In-Situ Gel for the Treatment of Wet Age-Related Macular Degeneration. Asian Journal of Pharmacy and Technology. 2025; 15(2):173-6. doi: 10.52711/2231-5713.2025.00027
Cite(Electronic):
Shivangi Das, Geetanjali Sahu, Suruchi Prasad. A Review on Formulation and Evaluation of In-Situ Gel for the Treatment of Wet Age-Related Macular Degeneration. Asian Journal of Pharmacy and Technology. 2025; 15(2):173-6. doi: 10.52711/2231-5713.2025.00027 Available on: https://ajptonline.com/AbstractView.aspx?PID=2025-15-2-11
REFERENCES:
1. Sharma A, Sharma US. Liposomes in drug delivery: progress and limitations. Int J Pharm. 1997; 154(2): 123-140.
2. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005; 4(2):145-160.
3. Langer R, Tirrell DA. Designing materials for biology and medicine. Nature. 2004; 428(6982):487-492.
4. Torchilin VP. Multifunctional nanocarriers. Adv Drug Deliv Rev. 2006; 58(14): 1532-1555.
5. Ghate D, Edelhauser HF. Ocular drug delivery. Expert Opin Drug Deliv. 2006;3(2):275-287.
6. Gaudana R, Jwala J, Boddu SH, Mitra AK. Recent perspectives in ocular drug delivery. Pharm Res. 2009;26(5):1197-1216.
7. Eljarrat-Binstock E, Domb AJ. Iontophoresis: a non-invasive ocular drug delivery. J Control Release. 2006;110(3):479-489.
8. Janagam DR, Wu L, Lowe TL. Nanoparticles for drug delivery to the anterior segment of the eye. Adv Drug Deliv Rev. 2017; 122: 31-64.
9. Wang Y, Challa P, Epstein DL, Yuan F. Controlled release of ethacrynic acid from poly (lactic-co-glycolic acid) films for glaucoma treatment. Biomaterials. 2004; 25(20):4279-4285.
10. Elsaid N, Jackson TL, Elsaid Z, Alqathama A, Somavarapu S. PLGA microparticles entrapping chitosan-based nanoparticles for the ocular delivery of ranibizumab. Mol Pharm. 2016; 13(9): 2923-2940.
11. Rubner R, Li KV, Canto-Soler MV. Progress of clinical therapies for dry age-related macular degeneration. Int J Ophthalmol. 2022 Jan 18; 15(1):157-166.
12. Jia Y, Bailey ST, Wilson DJ, et al. Quantitative optical coherence tomography angiography of choroidal neovascularization in age-related macular degeneration. Ophthalmology. 2014; 121(7):1435–1444.
13. Klein R, Meuer SM, Myers CE, et al. Harmonizing the classification of age-related macular degeneration in the three-continent AMD consortium. Ophthalmic Epidemiol 2019; 21: 14–23
14. Varsha R. Sandhan, S.B. Gondkar, R. B. Saudagar. Formulation Development of Ketoconazole Ophthalmic Formulation. Research J. Pharma. Dosage Forms and Tech. 2013; 5(6): 303-310.
15. Preeti K. Suresh, Abhishek K. Sah, Sanjay J. Daharwal. Role of free radicals in ocular diseases: An overview. Research J. Pharm. and Tech. 7(11): Nov. 2014 Page 1330-1344.
16. Erbas M, Sekerci H. Importance of free radicals and occurring during food processing. Serbest radïkallerïn onemï ve gida ïsleme sirasinda olusumu. 36; 2011:349-56.
17. Herrling T, Jung K, Fuchs J. The role of melanin as protector against free radicals in skin and its role as free radical indicator in hair. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy. 69; 2008:1429-35.
18. Frank RN, Amin RH, Puklin JE. Antioxidant enzymes in the macular retinal pigment epithelium of eyes with neovascular age-relatedmaculardegeneration, American Journal of Ophthalmology. 1999; 127: 694–709.
19. Zoric L. Parameters of oxidative stress in the lens. Aqueous humor and blood in patients with diabetes and senile cata-racts. Srp Arh Celok Lek. 2003; 131:137-42.
20. Ho M-C, Peng Y-J, Chen S-J, et al. Senile cataract and oxidative stress. J Clin Gerontol and Geriat. 2010; 1:17-21
21. Lodovici M, Caldini S, Morbidelli L, et al. Protective effect of 4-coumaric acid from UVB ray damage in the rabbit eye. Toxicol. 2009; 255: 1-5.
22. Saccà SC, Izzotti A. Oxidative stress and glaucoma: injury in the anterior segment of the eye. Prog Brain Res. 2008; 173: 385-407.
23. Caspi RR. A look at autoimmunity and inflammation of the eye. J Clin Invest. 2010; 120: 3073-83.
24. Schumacher S, Schlotzer-Schrehardt U, Martus P, et al. Pseudoexfolic syndrome and aneurysm of the abdominal aorta. Lancet. 2001;357:359-60.
25. Liu IY, White L, LaCroix AZ. The association of age-related macular degeneration and lens opacities in the aged. Am J Public Health. 1989; 79:765-69.